Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Nature Communications
|
May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy
Michael Schneider, Luca Paruzzo, Federico Stella, et al.
Journal of Cellular and Molecular Medicine
|
October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia
Ofrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
The New England Journal of Medicine
|
May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Jakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Nature Immunology
|
June 3, 2024
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer
Puneeth Guruprasad, Alberto Carturan, Yunlin Zhang, et al.
Nature Medicine
|
January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Guido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Blood
|
January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
Alberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Molecular Cancer
|
December 9, 2023
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Yunlin Zhang, Ruchi P Patel, Ki Hyun Kim, et al.
Cell
|
March 7, 2026
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer
Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, et al.
Nature Biomedical Engineering
|
March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
Gregory M Chen, Ankita Jain, David T Gering, et al.
Science Translational Medicine
|
February 4, 2026
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells
Ivan J Cohen, Audrey C Bochi-Layec, Jean Lemoine, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Nature Communications
|
May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy
Michael Schneider, Luca Paruzzo, Federico Stella, et al.
Journal of Cellular and Molecular Medicine
|
October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia
Ofrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
The New England Journal of Medicine
|
May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Jakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Nature Immunology
|
June 3, 2024
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer
Puneeth Guruprasad, Alberto Carturan, Yunlin Zhang, et al.
Nature Medicine
|
January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Guido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Blood
|
January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
Alberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Molecular Cancer
|
December 9, 2023
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Yunlin Zhang, Ruchi P Patel, Ki Hyun Kim, et al.
Cell
|
March 7, 2026
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer
Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, et al.
Nature Biomedical Engineering
|
March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
Gregory M Chen, Ankita Jain, David T Gering, et al.
Science Translational Medicine
|
February 4, 2026
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells
Ivan J Cohen, Audrey C Bochi-Layec, Jean Lemoine, et al.
Page
of 5